- Alliance Pharmaceutical has halted development of two of its contrast agents, Imagent BP and Imagent LN. The company added that it will phase out its already-marketed product, Imagent GI (perflubron), which was approved in the USA in 1993. The company cites unfavorable reimbursement conditions in the USA magnetic resonance imaging agent market as the reason for its decision. Alliance will now focus on the development of its ultrasound imaging agent Imagent US, its blood substitute Oxygent and the respiratory distress syndrome treatment LiquiVent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze